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ABSTRACT
Objective: The objective of the present work was to develop novel fixed-dose combinations (FDCs) for improvement of glucose tolerance in type II 
diabetes mellitus patients associated with dyslipidemia.
Methods: Multiple unit pellet systems (MUPSs) consisting of sustained release (SR) glimepiride and immediate release atorvastatin calcium pellets 
were formulated. The SR glimepiride pellets were prepared using a combination of locust bean gum and gum ghatti/guar gum. Similarly, the immediate 
release of atorvastatin calcium pellets was prepared using locust bean gum suspension as a binder.
Results: The formulated pellets were characterized using Fourier transform infrared spectroscopy (FTIR) and Differential scanning calorimetry 
(DSC). Further, surface morphology of the formulated pellets was done by scanning electron microscopy (SEM). FT-IR and DSC studies suggested that 
there were no chemical interactions between the drug and natural polymers. SEM studies revealed that formulated pellets were in spherical shape. 
Based on in vitro evaluation, the SR glimepiride formulation developed using a combination of 2% locust bean gum and 2.5% gum ghatti polymers 
sustained the release of the drug up to 12 h. Similarly, the immediate release atorvastatin calcium formulation containing 1% w/w locust bean gum 
suspension as a binder and 7% croscarmellose sodium showed fast disintegration of pellets. The in vivo studies in albino Wistar rat revealed that there 
was an improvement in bioavailability of the drugs. Stability studies showed that there were no significant changes in the drug content and physical 
appearance of the prepared SR glimepiride and immediate release atorvastatin pellet formulations.
Conclusion: Thus, the formulated FDC as MUPS can be used as an alternative approach for treating diabetes mellitus-induced dyslipidemia.
Keywords: Multiple unit pellet systems, Type II diabetes mellitus, Dyslipidemia glimepiride, Atorvastatin calcium.
INTRODUCTION
Diabetes mellitus (DM) is a heterogeneous metabolic disorder, 
characterized by impaired metabolism of glucose, lipids, and proteins. 
This is due to deficiency of insulin secretion or resistance to insulin 
action or both. If it is left untreated, it may lead to many complications 
such as diabetic ketoacidosis, retinopathy, neuropathy, nephropathy, 
cardiovascular complications, and ulceration or it may lead to death [1]. 
DM can be classified into two types. Type I DM is also known as insulin-
dependent DM and type II DM is known as non-insulin-dependent diabetes 
mellitus. Type II DM is very common compared to type I DM and estimated 
that more than 200 million people are suffering from diabetes [2].
In recent times, multiple unit pellet systems (MUPS) have grabbed the 
attention of pharmaceutical industries (API) among other formulations 
to treat diabetes-induced dyslipidemia as they deliver both immediate 
release and sustained release (SR) formulations in a single dosage. It 
is more advantageous when compared to other formulations due to its 
unique mechanical and physical properties [3]. Pellets can be delivered as 
both coated and uncoated form based on the release profile of the drug [4].
Glimepiride is the third-generation sulfonylurea. Glimepiride reduces 
the blood sugar level by stimulating the release of insulin by pancreatic 
beta-cells and increasing activity of intracellular insulin receptor. Due to 
its smaller biological half-life (5 h), it requires frequent administration. 
To reduce the dosing frequency, SR glimepiride formulations should be 
formulated to maintain the blood glucose levels [5].
Atorvastatin belongs to statin family. Atorvastatin is a synthetic lipid-
lowering drug. Atorvastatin is a selective, competitive inhibitor of 
HMG-CoA reductase. HMG-CoA reductase catalyzes the reduction of 
3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate. It also inhibits 
the task associated with cardiovascular diseases. Statins shall also 
reduce the blood levels of triglycerides and slightly increases the levels 
of high-density lipoprotein-cholesterol [6].
Here, in the current research work, a basic pellet formulation 
containing drugs and natural gums was formulated by employing the 
spheronization technique to modify the drug release using various 
concentrations to improve glucose tolerance in diabetes.
MATERIALS AND METHODS
Materials
Glimepiride and atorvastatin were purchased from Micro Labs, 
Bengaluru. Locust bean gum, gum ghatti, and guar gum were purchased 
from Loba Chemie, Mumbai. All other ingredients used were of analytical 
grade.
Methods
Preparation of drug-loaded SR glimepiride pellets
The preparation of glimepiride pellets was carried out using the extrusion/
spheronization process. Extrusion spheronization process involves four 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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steps as moistening the powder mixture, forming cylindrical shaped 
agglomerate through extrusion, breaking and rounding the extrudates to 
round pellets through spheronization, and drying the finished product. 
A uniform dry powder mixture (batch size 100 g) containing glimepiride, 
microcrystalline cellulose (MCC) (AvicelPH101), locust bean gum, and 
gum ghatti/guar gum in different concentrations was obtained by mixing 
in polyethylene bag for 10–15 min as shown in Table 1. The above mixture 
was then granulated using water and isopropyl alcohol in 5:2 ratio as 
granulation fluid. Then, the wet granulation mixture was extruded, and 
the extrudates were then immediately spheronized to yield the spherical 
pellets. The pellets were dried in a hot-air oven at 40°C for 10–12 h. The 
dried pellets were then filled and stored in screw-capped, high-density 
polyethylene bottles [7].
Preparation of drug-loaded immediate release atorvastatin calcium 
pellets
Similar to above glimepiride pellets formulation, the preparation 
of atorvastatin pellets was carried out using the extrusion/
spheronization process. Uniform dry powder mixture (batch size 
100 g) containing atorvastatin calcium and excipients such as MCC 
(AvicelPH101), sodium starch glycolate/croscarmellose sodium, 
sodium lauryl sulfate (SLS), and sodium bicarbonate was obtained 
in different concentrations by mixing it in a polyethylene bag for 10–
15 min as shown in Table 2. The mixture was then granulated by using 
1% w/w locust bean gum/PVPK-30 in water as granulation fluid. 
Then, the wet granulation mixture was extruded, and the extrudates 
were then immediately spheronized to yield the spherical pellets. The 
pellets were dried in a hot-air oven at 40°C for 10–12 h. The dried 
pellets were then filled and stored in screw-capped, high-density 
polyethylene bottles.
Characterization
Fourier transform infrared (FT-IR) studies of glimepiride and 
atorvastatin calcium
To determine the compatibility of the drug and polymer, FT-IR 
spectroscopy was used. Results were recorded using FT-IR (8400S, 
Shimadzu Corporation, Japan). API dispersed with KBR in a mortar, the 
material is triturated into a fine powder with the help of compression 
gauge, and the powder has been compressed in a holder. Moreover, the 
pressure of 5 ton is applied for 5 min, the pellet was placed in a light 
path, and the results were recorded [6].
Differential Scanning Calorimetry (DSC)
All DSC studies of pure drug and prepared formulations were carried 
out on Shimadzu Thermal Analyzer (TA-60WS). A few milligrams of the 
sample were entirely sealed into aluminum pans and heated under a 
nitrogen atmosphere with the heating rate of 10°C/min [8].
Solubility
Solubility studies of glimepiride and atorvastatin calcium were carried 
out using distilled water. Glimepiride and atorvastatin calcium were 
taken in vials containing distilled water. The vials were subjected 
to stirring for 24 h on a magnetic stirrer, and the obtained solution 
was filtered and the filtrate was estimated spectrophotometrically at 
Table 1: Formulation chart of sustained release glimepiride pellets
Ingredient concentration (%w/w) Wetting agent volume  
(water:IPA) (5:2) (mL/g)Formulation code Glimepiride MCC Locust bean gum Gum ghatti Gaur gum
BD-1 2.5 96.5 1 - - 0.80
BD-2 2.5 95.5 2 - - 0.77
BD-3 2.5 94.5 3 - - 0.77
BD-4 2.5 95.0 2 0.5 - 0.70
BD-5 2.5 94.5 2 1 - 0.77
BD-6 2.5 94.0 2 1.5 - 0.84
BD-7 2.5 93.5 2 2 - 0.84
BD-8 2.5 93.0 2 2.5 - 0.80
BD-9 2.5 95.0 2 - 0.5 0.74
BD-10 2.5 94.5 2 - 1 0.74
BD-11 2.5 94.0 2 - 1.5 0.80
BD-12 2.5 93.5 2 - 2 0.74
BD-13 2.5 93.0 2 - 2.5 0.80
MCC: Microcrystalline cellulose
Table 2: Formulation chart immediate release atorvastatin calcium pellets
Ingredient concentration (% w/w)
Formulation Atorvastatin calcium MCC SSG CCS Sodium bicarbonate SLS
FR-1 4 92 1 - 2 1
FR-2 4 91 2 - 2 1
FR-3 4 90 3 - 2 1
FR-4 4 89 4 - 2 1
FR-5 4 88 5 - 2 1
FR-6 4 87 6 - 2 1
FR-7 4 86 7 - 2 1
FR-8 4 92 - 1 2 1
FR-9 4 91 - 2 2 1
FR-10 4 90 - 3 2 1
FR-11 4 89 - 4 2 1
FR-12 4 88 - 5 2 1
FR-13 4 87 - 6 2 1
FR-14 4 86 - 7 2 1
FR-15 4 86 - 7 2 1
SLS: Sodium lauryl sulfate, MCC: Microcrystalline cellulose
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wavelengths of 249 nm for glimepiride and 246 nm for atorvastatin 
calcium, respectively [9].
pH of gums
The accurate measurement of pH was done using probe pH meter. The 
measurement was done by submerging the probe in the liquid until a 
reading is registered by the meter [9].
Micromeritic properties
Micromeritic properties for both glimepiride and atorvastatin calcium 
such as angle of repose, Carr’s index as well as tapped density were 
determined. The tapped density was determined using a tapped 
density tester, in which the glass cylinder was tapped 1000 times. 
The angle of repose is the most widely used method to check the 
flowability of pellets, which is done by measuring the height of the 
heap [10].
Scanning electron microscopy (SEM)
SEM photographs were taken with a SEM at the required magnification. 
The photographs were observed for morphological characteristics and 
to confirm spherical nature of the pellets. SEM was performed using 
Hitachi and SEM at 5 kV having different magnifications using Hitachi 
Noran System 7 manufactured by Thermo Fisher Scientific [10].
Evaluation of prepared pellets
Friability
Friability of pellets was determined by roche friabilator. 10 g of pellets 
were subjected to testing at 25 rpm for 4 min. Samples were sieved 
and the pellets retained on the sieve were weighed, and percentage 
friability was calculated from the difference in the weight of the pellets 
before and after friability.
Percentage yield
The yield of pellets was determined by the whole weight of pellets 
formed against the combined weights of drug, polymer, and other 
excipients.
Drug loading and entrapment efficiency
A specific amount of crushed pellets was suspended into freshly 
prepared 100 ml phosphate buffer of pH 6.8 with 0.5% w/v sodium 
lauryl sulfate with constant shaking at room temperature for 24 h. 
The final solutions were filtered, and the drug content and entrapment 
efficiency were measured for each formulation at specified wavelengths.
Pellet disintegration test
A tablet disintegration tester with a diameter of 10mm, length of 15mm 
and with a 710 mm mesh was used to estimate the disintegration time 
of the formulated pellets. After filling the tubes with pellets in each tube, 
they were inserted in the standard tablet disintegration tester and the 
temperature was maintained at 37°C, and the results were expressed 
in seconds [11].
In vitro dissolution studies
To study the in vitro dissolution profile, glimepiride pellets equivalent 
to 2.67 mg and atorvastatin calcium pellets equivalent to 10 mg were 
mixed together in fixed dose combination (FDC) and filled into the hard 
gelatin capsule. Electrolab USP dissolution testing apparatus I (basket 
type) was used to evaluate the rate of drug release from formulated 
pellets. A freshly prepared phosphate buffer of pH 6.8 with 0.5% w/v 
SLS (900 ml) was used as dissolution medium at 37±1°C, rotated at 
75 rpm. Withdrawn samples at pre-set time intervals were replaced 
with equal amounts of fresh buffer and samples were analyzed at the 
specified wavelengths [12].
In vivo studies
The study was conducted in accordance with the principles of laboratory 
animal care and was approved by the animal ethics committee.
Study design
A total of 12 albino Wistar rats of either sex weighing around 230–260 g 
were divided into two groups of six, namely control and test. For oral 
administration, optimized SR glimepiride (formulation BD-8) and 
immediate release atorvastatin calcium (formulation FR-14) pellet 
formulations were mixed in fixed dose ratio and administered to rats. 
The dose administered was 5 mg/kg of glimepiride and 25 mg/kg of 
atorvastatin calcium. Pure drugs, i.e., glimepiride and atorvastatin 
calcium were mixed in equivalent doses and dissolved in water (control) 
and administered orally using stomach sonde needle. Blood samples 
(0.3 ml) were obtained immediately before and after dosing at pre-
determined time intervals from the jugular vein. Samples were collected 
in heparinized tubes and were centrifuged for 5 min at 10,000 rpm at 
4°C. Plasma was separated and stored at −50°C for further analysis. 
Drug concentration in plasma samples (test and control) withdrawn at 
various time intervals was determined.
Pharmacokinetic and statistical analysis
The maximum plasma concentration (Cmax) and the time to reach 
peak plasma concentration (Tmax) were obtained directly from the 
concentration-time data. The elimination rate constant (K5) was obtained 
from the slope of the linear part of the elimination phase. The elimination 
half-life (t1/2) was calculated from 0.693/KE, while the area under the 
curve to the last measurable concentration (AUCM) was calculated by 
the linear trapezoidal rule. The area under the curve extrapolated to 
infinity (AUCMO) was obtained as AUCQ4+Ct/KE. The significance of the 
differences observed for the mean pharmacokinetic parameters of the 
test (FDC of optimized glimepiride and atorvastatin calcium pellets) and 
the combination of their respective pure drugs (control) was evaluated 
using Student’s t-test at a significance level of p<0.05 [13].
Stability studies
The optimized batches of SR Glimepiride and immediate release 
Atorvastatin calcium pellet formulations were mixed in FDC and filled 
into capsules, and finally, the capsules were placed in an aluminum 
pouch and heat-sealed. The packed formulation was subjected to 
stability studies at storage conditions such as 25±2°C/60±5% RH, 
30±2°C/65±5% RH, and 40±2°C/75±5% RH for 6 months. Samples 
were withdrawn on 0 day, 3 months, and 6 months and evaluated for 
their physical appearance, friability, and drug content [14,15].
RESULTS AND DISCUSSION
FT-IR studies of glimepiride
The position of the peak in FT-IR spectra of pure glimepiride is 
compared with those in FT-IR spectra of glimepiride with excipients as 
shown in Fig. 1. FT-IR spectral analysis indicated that the characteristic 
absorption peaks present in the IR spectra of glimepiride drug substance 
were also found in the physical mixtures of the polymers used (locust 
bean gum/gum ghatti/guar gum/microcrystalline cellulose) without 
any appreciable change in the position, attributing to the compatibility 
of drug–polymer. Hence, it can be concluded that drug can be used with 
the selected polymer without causing instability in the formulation.
FT-IR studies of atorvastatin calcium
The position of the peak in FT-IR spectra of pure atorvastatin calcium 
is compared with those in FT-IR spectra of atorvastatin calcium with 
excipients as shown in Fig. 2. FT-IR spectral analysis indicated that the 
characteristic absorption peaks present in the IR spectra of atorvastatin 
calcium drug substance were also found in the physical mixtures of the 
excipients used (microcrystalline cellulose/locust bean gum/sodium 
starch glycolate/croscarmellose sodium/sodium lauryl sulfate/sodium 
bicarbonate/PVP K-30) without any appreciable change in the position, 
attributing to the compatibility of drug–polymer. Hence, it can be 
concluded that drug can be used with the selected polymer without 
causing instability in the formulation.
DSC studies of glimepiride
As shown in Fig. 3, it was evident that glimepiride API DSC analysis 
shows a sharp endothermic peak at its melting point, i.e., at 207°C, 
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Fig. 1: Fourier transform infrared spectra of: (A) Glimepiride pure drug; (B) glimepiride+locust bean gum; (C) glimepiride+gum ghatti; 
(D) glimepiride+guar gum; (E) glimepiride+microcrystalline cellulose
Fig. 2: Fourier transform infrared spectra of: (A) Atorvastatin calcium pure drug; (B) atorvastatin calcium+microcrystalline cellulose; 
(C) atorvastatin calcium+sodium starch glycolate; (D) atorvastatin calcium+croscarmellose sodium; (E) atorvastatin calcium+sodium 
lauryl sulfate; (F) atorvastatin calcium+locust bean gum; (G) atorvastatin calcium+sodium bicarbonate; (H) atorvastatin calcium+PVP K-30
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indicating its crystalline nature of the drug. On the other hand, the DSC 
thermographs of formulation BD-2, BD-8, and BD-13 showed identical 
peaks to that of pure drug indicating the absence of chemical interaction 
between the drug and polymers.
DSC studies of atorvastatin calcium
The thermal analysis of pure atorvastatin calcium API showed a sharp 
endothermic peak at its melting point, i.e., at 156.87°C, demonstrating 
its crystalline nature. On the other hand, identical but broad peaks 
were found on DSC analysis of formulations FR-7, FR-14, and FR-15, 
indicating no interaction of atorvastatin calcium with its polymers and 
excipients. DSC thermograms of atorvastatin calcium API formulations 
FR-7, FR-14, and FR-15 are shown in Fig. 4.
Solubility
The solubility of glimepiride was found to be 4.38, 18.24, and 24.09 
g/L in pH 1.2, 6.8, and 7.2, respectively. Similarly, the solubility of 
atorvastatin calcium was found to be 6.84, 214.67, and 287.43 g/L in 
pH 1.2, 6.8, and 7.2 phosphate buffers, respectively. From the results, 
it can be inferred that both glimepiride and atorvastatin calcium were 
more soluble in alkaline pH, i.e., >7.
pH of gums
The locust bean gum is a non-ionic neutral polysaccharide and it 
reduces syneresis at a pH range of 5.6±0.49; pH of Guar gum obtained 
was 5.2±0.27. Ghatti gum having a pH range of 4.7±0.51 was favorable 
for the formulation of pellets.
Fig. 3: Differential scanning calorimetry thermogram of glimepiride, formulation BD-2, BD-8, and BD-13
Fig. 4: Differential scanning calorimetry thermogram of atorvastatin calcium attention of pharmaceutical industries, formulation FR-7, 
FR-14, and FR-15
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SEM studies of glimepiride
From the SEM photograph as shown in Fig. 5, it was observed that the SR 
glimepiride pellets formulated using locust bean gum and gum ghatti/
guar gum polymers exhibited spherical shape. The pellets consisting of 
locust bean gum alone and locust bean gum with gum ghatti polymer 
were of the smoother surface, while pellets prepared using guar gum 
along with locust bean gum showed chapped surface.
SEM studies of atorvastatin calcium
From the SEM photograph as shown in Fig. 6, it was observed that 
the immediate release atorvastatin calcium pellets formulated using 
1% w/w locust bean gum as a binder and sodium starch glycolate/
croscarmellose sodium exhibited spherical shape. The pellets 
consisting of locust bean gum and sodium starch glycolate were of the 
smoother surface, while pellets prepared using locust bean gum and 
croscarmellose sodium showed chapped surface.
Micromeritic properties of glimepiride
The micromeritic properties of different batches of SR glimepiride 
pellets are shown in Table 3. The properties such as average size (m), the 
angle of repose, tapped density, and Carr’s index revealed no significant 
difference among all batches. The angle of repose of all batches ranged 
between 23.20±1.35 and 27.35±1.58 indicating good flow properties of 
pellets. The bulk density results of different batches of SR glimepiride 
pellets indicated close packing settlement due to the narrow particle 
size distribution.
Micromeritic properties of atorvastatin calcium
The micromeritic properties of different batches of immediate release 
atorvastatin calcium pellets are shown in Table 4. The properties such 
as average size (mm), the angle of repose, tapped density, and Carr’s 
index revealed no significant difference among all batches. The angle 
of repose of all batches ranged between 24.19±1.33 and 27.46±1.37 
indicating good flow properties of pellets.
Evaluation of pellets
Friability and percentage yield glimepiride
The experimental results of the friability test and pellet yield of the 
SR glimepiride pellet formulations are summarized. The friability of 
the SR glimepiride pellet formulations were found to be in the range 
0.32±0.08–0.53±0.07%, and the results were in acceptable limits. The 
pellet yield was in the range of 76.9±2.31–83.3±3.16% in successive 
unit operations when 100 g of bulk material is being used.
Friability and percentage yield atorvastatin pellets
The experimental results of the friability test and pellet yield of 
the immediate release atorvastatin calcium pellet formulations are 
summarized. The friability of the immediate release atorvastatin 
calcium pellet formulations was found to be in the range 0.44±0.02–
0.54±0.05%, and the results were in acceptable limits. The pellet yield 
was in the range of 74.8±1.21–82.4±1.49% in successive unit operations 
when 100 g of bulk material is being used.
Drug loading and entrapment efficiency glimepiride
The drug-loading percentage in the formulations was found to be within 
2.28±0.23–2.55±0.15%. The encapsulation percentage was found to 
be 85.40±1.21–95.51±1.23%. From the results, it can be inferred that, 
Fig 6: Scanning electron microscopy of immediate release 
atorvastatin calcium pellets: (a) formulation FR-7 and (b) 
formulation FR-14 at different magnification
b
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Fig. 5: Scanning electron microscopy of sustained release 
glimepiride pellets: (a) formulation BD-2; (b) formulation BD-8; 

















BD-1 1135±51 25.14±1.24 1.05±0.03 0.84±0.04 9.12±0.32
BD-2 1189±25 26.42±1.18 1.03±0.04 0.86±0.07 8.79±0.24
BD-3 1245±23 25.45±1.26 1.08±0.03 0.90±0.03 9.39±0.21
BD-4 1224±35 23.20±1.35 1.05±0.02 0.89±0.06 8.93±0.34
BD-5 1318±27 27.21±1.30 1.12±0.06 0.83±0.05 8.76±0.30
BD-6 1336±32 26.48±1.44 1.04±0.08 0.83±0.05 8.69±0.37
BD-7 1361±37 25.16±1.15 1.06±0.07 0.84±0.07 8.85±0.24
BD-8 1380±21 26.65±1.88 1.09±0.05 0.90±0.03 9.39±0.36
BD-9 1262±73 26.83±1.28 1.08±0.06 0.89±0.04 8.93±0.29
BD-10 1294±42 26.25±1.36 1.16±0.04 0.83±0.05 8.76±0.38
BD-11 1359±32 24.68±1.54 1.02±0.03 0.83±0.07 8.69±0.41
BD-12 1331±33 25.66±1.15 1.07±0.04 0.84±0.06 8.85±0.35
BD-13 1397±23 27.35±1.58 1.05±0.02 0.90±0.04 9.39±0.44
*mean±SD, n=3, **˂0.05
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as polymer concentration increases, drug loading and encapsulation 
efficiency also increase. From the results, we can conclude that there 
Fig. 7: Disintegration time of different formulations of immediate 
release atorvastatin calcium pellets
is a proper distribution of glimepiride pellets and the deviations are in 
the acceptable limits.
Drug loading and encapsulation efficiency atorvastatin calcium
The drug-loaded percentage in the formulation was found to be within 
3.06±0.18–3.80±0.31%. The encapsulation percentage was found to 
be 87.15±0.96–95.19±1.76%. From the results, it can be inferred that 
there is a proper distribution of atorvastatin calcium in the pellets and 
the deviations are within the acceptable limits.
Pellet disintegration time
High disintegration time was observed for atorvastatin calcium 
pellets containing sodium starch glycolate as super disintegrant 
when compared to croscarmellose sodium. The results are mentioned 
graphically as shown in Fig. 7. The significant longer disintegration 
time for sodium starch glycolate containing pellets can be attributed 
to its disintegration mechanism, which acts by swelling on contact 
with the aqueous medium and further accompanied by gelling, which 
could possibly occlude the pores in the pellets prolonging further 
disintegration. Unlike sodium starch glycolate, the croscarmellose 
Fig. 8: (a-c) In vitro dissolution profile of sustained release glimepiride pellets
c
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FR-1 1127±41 25.14±1.52 1.09±0.04 0.79±0.05 8.11±0.42
FR-2 1177±30 26.42±1.24 1.04±0.02 0.81±0.04 8.19±0.49
FR-3 1255±43 25.25±1.46 1.07±0.08 0.80±0.05 9.21±0.44
FR-4 1274±45 24.19±1.33 1.03±0.06 0.75±0.05 8.01±0.18
FR-5 1371±50 27.21±1.69 1.05±0.04 0.76±0.04 8.24±0.80
FR-6 1204±57 26.18±1.27 1.05±0.06 0.83±0.03 9.09±0.41
FR-7 1140±27 25.06±1.29 1.08±0.03 0.80±0.05 8.21±0.61
FR-8 1208±32 26.65±1.47 1.06±0.05 0.84±0.02 8.54±0.54
FR-9 1219±44 26.55±1.24 1.02±0.04 0.81±0.04 8.05±0.87
FR-10 1244±37 26.04±1.35 1.07±0.06 0.85±0.05 8.46±1.03
FR-11 1247±42 24.54±1.42 1.01±0.05 0.79±0.02 8.21±1.13
FR-12 1265±47 27.46±1.37 1.05±0.04 0.81±0.05 8.48±0.14
FR-13 1341±34 26.35±1.41 1.08±0.03 0.80±0.05 9.04±0.22
FR-14 1280±29 26.41±1.35 1.07±0.04 0.82±0.03 8.47±0.27
FR-15 1318±36 27.11±1.32 1.04±0.05 0.81±0.06 8.21±0.60
*mean±SD, n=3, **˂0.05
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sodium has a dual functional mechanism of disintegration, i.e., water 
wicking and rapid swelling, leading to superior disintegration 
characteristics than sodium starch glycolate, which is the rate-limiting 
step for dissolution of the drug.
In vitro dissolution studies of SR GLIMEPIRIDE and immediate 
release atorvastatin calcium pellets in FDC
Various formulations of SR glimepiride and immediate release 
atorvastatin calcium were evaluated for the in vitro study as shown in 
Figs. 8a-c and 9a and b. Among all the formulations of SR glimepiride 
pellets, BD-8 had sustained the drug release up to 12 h. Among all 
the formulations of immediate release atorvastatin calcium pellets, 
FR-14 was considered to be optimized because it shows faster drug 
release of 89.32±2.4% which contains 1% locust bean and 7% w/v 
croscarmellose sodium.
In vivo studies of SR glimepiride and immediate release 
atorvastatin calcium pellets in FDC
A comparative plasma profile was performed between both Glimepiride 
and Atorvastatin API and its respective optimized formulations BD-8 
and FR-14. As shown in Table 5 and Fig. 10, the results show that 
formulation BD-8 was found to be more significant than glimepiride 
API with respect to bioavailability and the formulation FR-14 was found 
to be more significant than atorvastatin API with respect to relative 
bioavailability. Table 6 summarizes the pharmacokinetic parameters 
of FDC of glimepiride API with atorvastatin calcium API and of the 
optimized SR glimepiride pellet formulation (BD-8) with optimized 
immediate release atorvastatin calcium pellet formulation (FR-14).
Table 5: Plasma profile of sustained release glimepiride and immediate release atorvastatin pellets
Time (h) Plasma drug concentration (ng/ml)*
Glimepiride API Formulation BD 8 Atorvastatin calcium API Formulation FR 14
0.5 0786.2±134.18 0319.21±112.14 138.21±40.53 383.16±73.11
1.0 1123.10±170.24 0433.32±148.49 348.02±66.07 614.03±91.44
1.5 1435.60±184.5 0653.58±173.53 316.33±63.34 573.88±84.32
2.0 1847.20±210.14 0967.30±193.66 299.28±51.76 494.90±73.41
3.0 2238.80±220.79 1276.37±207.18 263.67±59.29 433.67±68.37
4.0 3219.52±286.34 1655.53±229.04 227.39±61.51 315.21±59.65
6.0 1862.67±178.79 1883.20±267.39 186.20±34.40 234.01±66.51
8.0 862.21±127.26 1534.19±193.91 139.16±29.16 167.44±38.14
10.0 393.05±83.70 1243.11±177.83 112.53±31.26 121.36±35.32
12.0 26.44±14.15 864.35±164.40 84.30±27.33 90.21±31.40
24.0 9.13±3.83 367.54±8.64 6.09±3.32 8.61±5.86
*mean±SD, n=3, API: Attention of pharmaceutical industries
Table 6: Summary of pharmacokinetic parameter after oral administration of glimepiride API and atorvastatin calcium API in FDC and 
also their respective optimized formulation, i.e., formulation BD-8 and Formulation FR-14 in FDC to rat
Parameters Cmax (ng/mL) Tmax (h) t1/2 (h) Ket (h-1) AUC0-24h (ng/mL) AUC0‑∞ (ng/mL)
Glimepiride API 3219.52±286.36 4.0±0 2.28±0.11 0.3053±0.019 9689.1±87.3 9718.47±45.2
Formulation BD-8 1883.20±267.39 6.0±0 7.72±0.15 0.0898±0.0024 15687.2±103.7 19771.07±34.4
Atorvastatin calcium API 348.02±66.27 1.0±0 4.08±0.17 0.1695±0.021 2570.5±97.5 2606.14±64.6
Formulation FR-14 614.03±91.24 1.0±0 3.72±0.19 0.1859±0.026 3438.1±88.3 3481.01±73.3
FDC: Fixed-dose combinations, API: Attention of pharmaceutical industries, *mean±SD, n=3




25±2°C/60±5% RH 30±2°C/65±5% RH 40±2°C/75±5%
Friability Drug content (%) Friability Drug content (%) Friability Drug content (%)
BD 7 FR 14 BD 7 FR 14 BD 7 FR 14
0 0.39±0.41 98.7±0.20 99.1±0.53 0.37±0.41 99.04±0.35 98.71±0.80 0.37±0.84 98.14±0.49 99.14±0.30
3 0.44±0.23 99.2±0.18 98.5±0.84 0.47±0.73 98.56±0.06 98.53±0.22 0.56±0.51 99.33±0.66 97.89±0.71
6 0.51±0.66 98.0±0.73 97.9±0.67 0.54±0.16 98.88±0.10 07.95±0.51 0.64±0.90 99.61±0.18 98.38±0.65
*mean±SD, n=3
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Fig. 10: Plasma drug concentration versus time profile of optimized formulations and their respective attention of pharmaceutical 
industries
Stability studies
Stability studies of FDC formulation of SR glimepiride formulation 
(BD-8) and immediate release atorvastatin formulation (FR-14) 
pellets were carried out at various temperature and humidity such 
as 25±2°C/60±5%, 30±2°C/65±5% RH, and 40±2°C/75±5% RH. 
Formulations were subjected to various evaluation parameters. The 
results are shown in Table 7. From the results, it can be confirmed that 
there were no significant changes in physicochemical properties of the 
SR glimepiride formulation (BD-8) and immediate release atorvastatin 
formulation FR-14.
CONCLUSION
There is a strong prophylactic and clinical need to develop novel fixed 
combination delivery systems for improvement of glucose tolerance 
in type II diabetes patients associated with dyslipidemia with desired 
characteristics such as better therapeutic efficacy, convenience, 
reduced pill burden, and simplified administration of regiments with 
cost-effective medication. The developed fixed-dose, combination 
dosage forms, namely MUPS, have demonstrated its superiority in the 
improvement of metabolic disorders. Thus, the study demonstrates 
that the developed FDC systems have a great appeal for the convenient 
treatment of diabetic dyslipidemia that may be explored in improving 
the limitation of existing monotherapy drug delivery systems.
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